Forte Biosciences' FB102 achieves statistically significant results in phase 1b vitiligo trial

Forte Biosciences announced positive results from a double-blind placebo-controlled study where FB102 improved vitiligo severity by 29.6% through week 24. Continued post-treatment efficacy and safety support the drug's therapeutic potential.